PIRAMAL PHARMA Results Analysis-Q2FY2027

PPLPHARMA Financial performance and key operating metrics (Consolidated) : Operating Revenue for Q2FY27 is Rs. 2,617 Crs., 28.05% growth YoY, Total Income is Rs. 2,653 Crs., 25.77% growth YoY, Gross Profit is Rs. 1,711 Crs., 27.56% growth YoY, EBITDA is Rs. 385 Crs., 71.51% growth YoY, EBITDA Margin is 14.5% improved by 387 Basis points YoY, PBT Rs. 82 Crs. in comparison to loss of Rs. 46 Cr. in PY, PAT Rs. 5 Crs. in comparison to loss of Rs. 99 Cr. in PY. On QoQ basis Op. Revenue is up by 15.29%, Total Income is up by 12.45%, EBITDA is up by 35.16%, PBT turned profitable from loss of Rs. 7 Cr., PAT is also turned profitable from loss of Rs. 69 Cr. Margin step-up primarily to operating leverage from better capacity utilization, with disciplined execution, productivity and cost management. CDMO : Q2 CDMO revenue: ₹1,424 cr (+36% YoY), Complex Hospital Generics (CHG) : Q2 CHG revenue: ₹849 cr (+32% YoY) Consumer Healthcare: Q2 revenue: ₹359 cr (+13% YoY) Net debt increased over six months due to Lexington expansion, Kenalog acquisition, and currency impact.